367 related articles for article (PubMed ID: 30361677)
1. Lipid management in patients with chronic kidney disease.
Ferro CJ; Mark PB; Kanbay M; Sarafidis P; Heine GH; Rossignol P; Massy ZA; Mallamaci F; Valdivielso JM; Malyszko J; Verhaar MC; Ekart R; Vanholder R; London G; Ortiz A; Zoccali C
Nat Rev Nephrol; 2018 Dec; 14(12):727-749. PubMed ID: 30361677
[TBL] [Abstract][Full Text] [Related]
2. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
Reiner Z
Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
[TBL] [Abstract][Full Text] [Related]
3. Management of dyslipidaemia in patients with chronic kidney disease: a position paper endorsed by the Italian Society of Nephrology.
Pontremoli R; Bellizzi V; Bianchi S; Bigazzi R; Cernaro V; Del Vecchio L; De Nicola L; Leoncini G; Mallamaci F; Zoccali C; Buemi M
J Nephrol; 2020 Jun; 33(3):417-430. PubMed ID: 32065354
[TBL] [Abstract][Full Text] [Related]
4. Should we use statins in all patients with chronic kidney disease without dialysis therapy? The current state of knowledge.
Rysz J; Gluba-Brzózka A; Banach M; Więcek A
Int Urol Nephrol; 2015 May; 47(5):805-13. PubMed ID: 25758011
[TBL] [Abstract][Full Text] [Related]
5. [HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia].
Bajnok L
Orv Hetil; 2014 Jan; 155(2):62-8. PubMed ID: 24389322
[TBL] [Abstract][Full Text] [Related]
6. Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline.
Tonelli M; Wanner C;
Ann Intern Med; 2014 Feb; 160(3):182. PubMed ID: 24323134
[TBL] [Abstract][Full Text] [Related]
7. Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: assessment of clinical usefulness in CKD patients with atorvastatin (ASUCA) trial.
Kimura G; Kasahara M; Ueshima K; Tanaka S; Yasuno S; Fujimoto A; Sato T; Imamoto M; Kosugi S; Nakao K
Clin Exp Nephrol; 2017 Jun; 21(3):417-424. PubMed ID: 27392909
[TBL] [Abstract][Full Text] [Related]
8. Dyslipidemia in patients with chronic kidney disease.
Hager MR; Narla AD; Tannock LR
Rev Endocr Metab Disord; 2017 Mar; 18(1):29-40. PubMed ID: 28000009
[TBL] [Abstract][Full Text] [Related]
9. [Clinical practice guidelines for the management of dyslipidemia in chronic kidney disease].
Shoji T
Nihon Jinzo Gakkai Shi; 2013; 55(7):1267-75. PubMed ID: 24288962
[No Abstract] [Full Text] [Related]
10. 2017 Taiwan lipid guidelines for high risk patients.
Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
[TBL] [Abstract][Full Text] [Related]
11. Ongoing challenges for pharmacotherapy for dyslipidemia.
Pisaniello AD; Scherer DJ; Kataoka Y; Nicholls SJ
Expert Opin Pharmacother; 2015 Feb; 16(3):347-56. PubMed ID: 25476544
[TBL] [Abstract][Full Text] [Related]
12. Management of dyslipidaemias in the elderly population-A narrative review.
Anagnostis P; Vaitsi K; Veneti S; Georgiou T; Paschou SA; Lambrinoudaki I; Goulis DG
Maturitas; 2019 Jun; 124():93-99. PubMed ID: 30910278
[TBL] [Abstract][Full Text] [Related]
13. Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease.
Mathew RO; Rosenson RS; Lyubarova R; Chaudhry R; Costa SP; Bangalore S; Sidhu MS
Cardiovasc Drugs Ther; 2021 Jun; 35(3):479-489. PubMed ID: 32556851
[TBL] [Abstract][Full Text] [Related]
14. Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease.
Katsiki N; Mikhailidis DP; Banach M
Expert Opin Pharmacother; 2019 Nov; 20(16):2007-2017. PubMed ID: 31344332
[No Abstract] [Full Text] [Related]
15. KDOQI US commentary on the 2013 KDIGO Clinical Practice Guideline for Lipid Management in CKD.
Sarnak MJ; Bloom R; Muntner P; Rahman M; Saland JM; Wilson PW; Fried L
Am J Kidney Dis; 2015 Mar; 65(3):354-66. PubMed ID: 25465166
[TBL] [Abstract][Full Text] [Related]
16. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
Virani SS; Kennedy KF; Akeroyd JM; Morris PB; Bittner VA; Masoudi FA; Stone NJ; Petersen LA; Ballantyne CM
Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e004652. PubMed ID: 29748356
[TBL] [Abstract][Full Text] [Related]
17. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
[TBL] [Abstract][Full Text] [Related]
18. Nonstatin therapies for management of dyslipidemia: a review.
Sando KR; Knight M
Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799
[TBL] [Abstract][Full Text] [Related]
19. Precision Medicine and Personalized Management of Lipoprotein and Lipid Disorders in Chronic and End-Stage Kidney Disease.
Streja E; Streja DA; Soohoo M; Kleine CE; Hsiung JT; Park C; Moradi H
Semin Nephrol; 2018 Jul; 38(4):369-382. PubMed ID: 30082057
[TBL] [Abstract][Full Text] [Related]
20. [Statins: what is their place in the treatment of chronic kidney insufficiency?].
Ponte B; Bourquin V; Stoermann-Chopard C
Rev Med Suisse; 2009 Feb; 5(192):463-4, 466-8. PubMed ID: 19317313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
